Radiopharmaceuticals have evolved from pioneering thyroid cancer treatments to cutting-edge therapies like Lutathera for neuroendocrine tumors and Pluvicto for PSMA-positive prostate cancer.
Peptide-based diagnostics, like gallium-68 DOTATATE, enhance cancer imaging and detection with greater sensitivity and specificity, enabling earlier and more precise disease monitoring.
Ariceum Therapeutics showcased significant findings on 225Ac-Satoreotide, a novel radiopharmaceutical, at the European Association of Nuclear Medicine 2024 conference. The drug demonstrated superior anti-tumour efficacy and pharmacokinetic profile compared to DOTA-TATE, marking a potential breakthrough in treating SSTR2-positive cancers.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.